Vantage Investment Advisors LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 11.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,584 shares of the company’s stock after selling 465 shares during the quarter. Vantage Investment Advisors LLC’s holdings in Eli Lilly and were worth $295,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of LLY. Heritage Trust Co purchased a new stake in Eli Lilly and during the first quarter valued at $135,000. Point72 Asia Hong Kong Ltd increased its position in Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after acquiring an additional 1,239 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new stake in Eli Lilly and during the second quarter valued at $148,000. Cornerstone Advisors Inc. increased its position in Eli Lilly and by 18.4% during the second quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock valued at $166,000 after acquiring an additional 313 shares during the last quarter. Finally, Penserra Capital Management LLC increased its position in Eli Lilly and by 9.5% during the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after acquiring an additional 176 shares during the last quarter. Institutional investors own 75.66% of the company’s stock.
Eli Lilly and Company (LLY) opened at $83.51 on Friday. The company has a market capitalization of $91.53 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 1.83 and a beta of 0.34. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.01.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.88 earnings per share. equities analysts predict that Eli Lilly and Company will post 4.22 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is presently 98.58%.
A number of analysts recently commented on the company. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a research report on Wednesday. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research report on Thursday, October 26th. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Leerink Swann cut Eli Lilly and from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $93.00 to $90.00 in a research report on Wednesday, July 26th. Finally, Cowen and Company reiterated a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and a consensus price target of $89.76.
ILLEGAL ACTIVITY WARNING: “Eli Lilly and Company (LLY) Stake Decreased by Vantage Investment Advisors LLC” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/11/04/eli-lilly-and-company-lly-stake-decreased-by-vantage-investment-advisors-llc.html.
In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders have sold 770,000 shares of company stock valued at $64,669,850. 0.20% of the stock is owned by corporate insiders.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.